Compare AIP & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIP | NBTX |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | 2021 | 2018 |
| Metric | AIP | NBTX |
|---|---|---|
| Price | $44.50 | $35.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $16.83 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 981.9K | 49.3K |
| Earning Date | 05-12-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.65 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $70,579,000.00 | N/A |
| Revenue This Year | $30.24 | $58.17 |
| Revenue Next Year | $19.50 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 22.27 | N/A |
| 52 Week Low | $8.42 | $4.57 |
| 52 Week High | $44.94 | $57.14 |
| Indicator | AIP | NBTX |
|---|---|---|
| Relative Strength Index (RSI) | 68.92 | 43.66 |
| Support Level | $13.38 | $30.15 |
| Resistance Level | N/A | $41.89 |
| Average True Range (ATR) | 2.96 | 2.61 |
| MACD | 0.46 | -0.14 |
| Stochastic Oscillator | 90.61 | 54.77 |
Arteris Inc is a provider of semiconductor system IP, including interconnect and other intellectual property, (collectively, System IP) technology. Its IP technology manages the on-chip communications and IP block deployments in System-on-Chip (SoC) semiconductors and systems of chiplets. Its proprietary System IP solutions achieve this by connecting client IP blocks such as processors, memories, artificial intelligence/machine learning (AI/ML) accelerators, graphics subsystems, safety and security, and other input/output subsystems (I/Os) via multiple Network-on-Chips (NoCs). The company operates in Americas, Asia Pacific and Europe, Middle East, out of which it derives maximum its revenue from Asia Pacific.
Nanobiotix SA is a late-stage clinical biotechnology company focused on re-inventing medicine by building new therapies atom by atom, developing widely applicable, first-in-class, physics-based nanotherapeutics to transform treatment outcomes and expand life for millions of patients. The objective of this physics-based approach is to allow nanoparticles to be combined with other drugs or therapeutic modalities and to integrate seamlessly into clinical practice without adding burden for the patient, healthcare provider, or healthcare system. It has three platforms Nanoradioenhancer platform: Nanoprimer platform: and Neurological disease platform. It has one segment, which is the research and development of product candidates that use proprietary nanotechnology to transform cancer treatment.